AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17852947
Drug: Alternate-day administration
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate-day administration of amphotericin B deoxycholate (2 mg/kg)
Trial: 9522109
Drug: Nabumetone 2000
RxNorm normalized name: Nabumetone
DrugBank: Nabumetone (DB00461)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nabumetone 2000 mg daily
Trial: 2390432
Drug: Acipimox 250
RxNorm normalized name: acipimox 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox 250 mg three times daily and cholestyramine 4 g three times daily
Trial: 2390432
Drug: Acipimox added
RxNorm normalized name: acipimox
DrugBank: Acipimox (DB09055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox added to cholestyramine therapy
Trial: 7409937
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of pentobarbital
Trial: 30650260
Drug: ELX-02 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELX-02 (0.3 mg/kg to 7.5 mg/kg)
Trial: 23592830
Drug: EFV (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EFV (600 mg) on-RIF
Trial: 23592830
Drug: EFV (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EFV (600 mg) off-RIF
Trial: 17078771
Drug: Fasting therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting therapy (FT) consisting of 10 days of starvation followed by 5 days of refeeding
Trial: 17078771
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy (basic treatment consisting of pharmacotherapy and brief psychotherapy)
Trial: 31906748
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (MT) - a single individualized session along with a recorder and journal for home use
Trial: 31906748
Drug: Music Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music Plus - weekly group MT sessions along with a recorder and journal for home use
Trial: 30919549
Drug: Biomarker-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker-guided treatment strategy
Trial: 28654556
Drug: Sufentanil 100
RxNorm normalized name: SUFentanil 100 MCG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 100 μg + dexmedetomidine 200 μg + normal saline 100 mL (group D)
Trial: 28654556
Drug: Sufentanil 100
RxNorm normalized name: SUFentanil 100 MCG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 100 μg + normal saline 100 mL (group C)
Trial: 25526455
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for older patients with stage II disease
Trial: 25526455
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for older patients with stage III disease
Trial: 25526455
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for older patients with colon cancer
Trial: 25526455
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for older patients with rectal cancer
Trial: 25526455
Drug: Preoperative short-course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative short-course radiotherapy for older patients with stage III rectal cancer
Trial: 25526455
Drug: Preoperative short-course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative short-course radiotherapy for older patients with rectal cancer
Trial: 25526455
Drug: Surgery for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery for rectal cancer patients aged ≥80 years
Trial: 21972424
Drug: Atorvastatin 20mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20mg daily for three months
Trial: 21972424
Drug: Metformin 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1500 mg daily for three months (after atorvastatin)
Trial: 21972424
Drug: Metformin 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1500 mg daily for three months (after placebo)
Trial: 15939064
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (2.5 mg), Vitamin B6 (25 mg), Vitamin B12 (0.5 mg)
Trial: 1955196
Drug: Troleandomycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troleandomycin (1 g bid over a 10‐day period)
Trial: 1955196
Drug: Josamycin (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Josamycin (same doses as T)
Trial: 25424602
Drug: Rapeseed oil
RxNorm normalized name: Rapeseed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapeseed oil (RO) diet (14-27 g/day) for 13 weeks
Trial: 25424602
Drug: Sunflower oil
RxNorm normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower oil (SO) diet (14-27 g/day) for 13 weeks
Trial: 23172400
Drug: Prescription-oriented (Pr‐O)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription-oriented (Pr‐O) approach
Trial: 17530483
Drug: Thalidomide alone
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide alone (200 mg/day up to 800 mg/day)
Trial: 15005733
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) only (n=16)
Trial: 15005733
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) + one dose of BCG immunization (n=16)
Trial: 15005733
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (inhaled therapy only, PPD-negative asthmatics allergic to HDM, n=5)
Trial: 9722121
Drug: Single-dose piperacillin
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose piperacillin (4 g)
Trial: 9722121
Drug: Multi-dose piperacillin
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multi-dose piperacillin (3 doses of 2 g)
Trial: 9722121
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cephradine and metronidazole (3 doses)
Trial: 9722121
Drug: Single-dose piperacillin
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose piperacillin vs. multi-dose piperacillin
Trial: 8057223
Drug: spray-dried powder
RxNorm normalized name: Lactose, Monohydrate, Spray-Dried Powder, NF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spray-dried powder formula
Trial: 2971692
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg acitretin
Trial: 2971692
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg acitretin
Trial: 2971692
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg acitretin
Trial: 2971692
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg etretinate
Trial: 2971692
Drug: All acitretin
RxNorm normalized name: Acitretin
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All acitretin doses and etretinate
Trial: 2971692
Drug: Acitretin treatment
RxNorm normalized name: Acitretin
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acitretin treatment
Trial: 2971692
Drug: 3 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 weeks after cessation of treatment
Trial: 26477278
Drug: FBZ >10mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FBZ >10mg/kg once daily for five consecutive days
Trial: 26477278
Drug: moxidectin (MOX)
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: moxidectin (MOX) >0.4 mg/kg once
Trial: 21568746
Drug: Tripterygium hypoglaucum
RxNorm normalized name: Tripterygium wilfordii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium hypoglaucum Hutch (THH) 3 tablets 3 times daily
Trial: 21568746
Drug: Placebo 3
RxNorm normalized name: placebo 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3 tablets 3 times daily
Trial: 21568746
Drug: THH with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THH with cetirizine hydrochloride 10 mg once daily
Trial: 21568746
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with cetirizine hydrochloride 10 mg once daily
Trial: 18491970
Drug: Valganciclovir (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir (900 mg once per day for 8 weeks)
Trial: 16487695
Drug: Piperacillin/tazobactam (P/T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (P/T) 4 g/500 mg every 6 h
Trial: 16487695
Drug: Imipenem/cilastatin (IMP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (IMP) 500 mg/500 mg every 6 h
Trial: 11832093
Drug: Intraperitoneal lymphatic
RxNorm normalized name: PINPOINT Lymphatics Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal lymphatic chemotherapy with carboplatin (200 mg) and sandostatin (0.1 mg x 2)
Trial: 11832093
Drug: Intraperitoneal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal chemotherapy with carboplatin (200 mg)
Trial: 1630846
Drug: Dextropropoxyphene hydrochloride
RxNorm normalized name: Dextropropoxyphene hydrochloride
DrugBank: Dextropropoxyphene (DB00647)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextropropoxyphene hydrochloride (DP) 150 mg, twice a day, in a double-blind, randomized, placebo-controlled, crossover trial.
Trial: 30854880
Drug: Calcitonin gene-related
RxNorm normalized name: Calcitonin gene-related peptide
DrugBank: Calcitonin gene-related peptide (DB06379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin gene-related peptide (1.5 µg/min)
Trial: 21985500
Drug: Oral nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nifedipine (10 mg tablet, orally, up to five doses)
Trial: 21985500
Drug: Intravenous labetalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous labetalol (escalating doses of 20, 40, 80, 80 and 80 mg)
Trial: 2478426
Drug: Starch (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch (50 g) pudding meal (400 ml) with water (200 ml)
Trial: 2478426
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with water (200 ml)
Trial: 2478426
Drug: Amylase inhibitor
RxNorm normalized name: amylase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amylase inhibitor (5 or 10 g) with water and starch
Trial: 2478426
Drug: Amylase inhibitor
RxNorm normalized name: amylase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amylase inhibitor (4 g) with water and starch
Trial: 2478426
Drug: Amylase inhibitor
RxNorm normalized name: amylase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amylase inhibitor (5 or 10 g)
Trial: 796954
Drug: Aspirin (soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (soluble form of acetylsalicylic acid)
Trial: 28596023
Drug: Oligofructose-enriched inulin
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oligofructose-enriched inulin (OI; 8 g/day)
Trial: 28596023
Drug: Maltodextrin placebo
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin placebo (isocaloric dose)
Trial: 25939604
Drug: Circulating LCN2
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Circulating LCN2 levels above the median (76.6 ng/mL)
Trial: 23863583
Drug: Water group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water group - patients drank 500 mL water after dinner on the evening before endoscopy, and 350 mL water before the examination.
Trial: 21954526
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg morphium hydrochloride (MCh)
Trial: 21954526
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg morphium hydrochloride (MCh)
Trial: 9316951
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous meperidine analgesia
Trial: 3742833
Drug: Melatonin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (2 mg daily in 5 ml corn-oil)
Trial: 19066295
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human GH (0.5 mg every day) plus standardized diet and exercise program
Trial: 17166305
Drug: Unilateral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral treatment
Trial: 17166305
Drug: Bilateral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral treatment
Trial: 9861119
Drug: Nimodipine 10
RxNorm normalized name: nimodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 10 ml h‐1 (group N)
Trial: 7714107
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg Dex (1 mg at midnight the previous night and 0.5 mg at 0700 h on the day of the test) + 3 x 10(6) IU iv IFN‐alpha 2
Trial: 7714107
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg Dex (1 mg at midnight the previous night and 0.5 mg at 0700 h on the day of the test) + 2 mL iv saline
Trial: 7714107
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL iv saline
Trial: 1259521
Drug: Phenothiazines (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenothiazines (twice daily schedule)
Trial: 23415543
Drug: Levodopa (L-DOPA)
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa (L-DOPA) treatment
Trial: 21812263
Drug: Astragalus Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus Injection (2 mL/kg)
Trial: 19442784
Drug: Doxycycline (DOX;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (DOX; 20 mg) twice a day
Trial: 19442784
Drug: Levonorgestrel-releasing subcutaneous
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel-releasing subcutaneous implant (LNG SI)
Trial: 16928840
Drug: Ethyl vinyl
RxNorm normalized name: METHYL VINYL ETHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethyl vinyl chloride vapocoolant spray
Trial: 16928840
Drug: Isopropyl alcohol
RxNorm normalized name: Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isopropyl alcohol spray (placebo)
Trial: 11343405
Drug: Activities where
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities where participant was the agent of action.
Trial: 8186064
Drug: Oxitropium bromide
RxNorm normalized name: oxitropium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxitropium bromide (200 micrograms three times daily)
Trial: 30462938
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus GG (1×10^10 CFU twice daily for 5 days)
Trial: 23297772
Drug: Amoxicillin (AMX,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (AMX, 500 mg) + Metronidazole (MET, 250 mg), TID for 10 days
Trial: 20492045
Drug: Chinese food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese food therapy (specific dietary instructions, management of antihypertensive medication, brief health education)
Trial: 20492045
Drug: Chinese food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese food therapy
Trial: 12580992
Drug: Garlic supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic supplements (10 mg of Natural Source Odourless Garlic)
Trial: 10867376
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving only pharmacotherapy
Trial: 10867376
Drug: D. Pteronyssinus
RxNorm normalized name: D. farinae extract 6 SQ-HDM / D. pteronyssinus extract 6 SQ-HDM Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D. Pteronyssinus immunotherapy
Trial: 10867376
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving medication only
Trial: 6685418
Drug: Hormonal treatment
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal treatment for mastopathy
Trial: 6685418
Drug: Non-hormonal treatment
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-hormonal treatment for mastopathy
Trial: 6685418
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment of mastopathy
Trial: 26768126
Drug: Subcutaneous (s.c.)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c.) TBE vaccination
Trial: 26768126
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) TBE vaccination
Trial: 22483860
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no PRGF treatment)
Trial: 20618356
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion (0.1 nmol kg⁻¹ min⁻¹)
Trial: 15922478
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg emtricitabine once daily
Trial: 15922478
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg emtricitabine once daily
Trial: 15922478
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg emtricitabine once daily
Trial: 15922478
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg emtricitabine open-label after 48 weeks
Trial: 10370678
Drug: Intra-arterial chemotherapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial chemotherapy with doxorubicin 50 mg/m2
Trial: 10370678
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy with doxorubicin 50 mg/m2
Trial: 8677192
Drug: Water, Na,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water, Na, Ca, Mg, and oxalic acid excretion in patients with ARSD under water immersion (IW)
Trial: 8677192
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between serum ANP levels and urinary excretion of Na, Ca, and Mg in patients with ARSD
Trial: 8677192
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between serum ANP levels and urinary excretion of oxalic acid in patients with ARSD during water immersion (IW)
Trial: 6626018
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% aqueous suspension
Trial: 6626018
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% oil suspension
Trial: 26209003
Drug: Loop diuretics
RxNorm normalized name: LOOP DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loop diuretics (40 mg furosemide equivalents)
Trial: 22421631
Drug: Nebivolol (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (10-40 mg/day, titrated based on BP response)
Trial: 12242072
Drug: Group CTL
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group CTL (non-treatment of atrial fibrillation relapse)
Trial: 24533697
Drug: Pasireotide 600/900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 600/900 μg bid
Trial: 22145743
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene educational programs
Trial: 22145743
Drug: Frequency of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequency of oral hygiene behaviour at 3 months
Trial: 17551129
Drug: 1 mg/d
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/d of folic acid